859 related articles for article (PubMed ID: 27147666)
1. Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase Signaling Pathway.
Renard J; Loureiro M; Rosen LG; Zunder J; de Oliveira C; Schmid S; Rushlow WJ; Laviolette SR
J Neurosci; 2016 May; 36(18):5160-9. PubMed ID: 27147666
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol Modulates Fear Memory Formation Through Interactions with Serotonergic Transmission in the Mesolimbic System.
Norris C; Loureiro M; Kramar C; Zunder J; Renard J; Rushlow W; Laviolette SR
Neuropsychopharmacology; 2016 Nov; 41(12):2839-2850. PubMed ID: 27296152
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1-2 Phosphorylation.
Hudson R; Renard J; Norris C; Rushlow WJ; Laviolette SR
J Neurosci; 2019 Oct; 39(44):8762-8777. PubMed ID: 31570536
[TBL] [Abstract][Full Text] [Related]
4. Ventral Tegmental Area Dopamine Cell Activation during Male Rat Sexual Behavior Regulates Neuroplasticity and d-Amphetamine Cross-Sensitization following Sex Abstinence.
Beloate LN; Omrani A; Adan RA; Webb IC; Coolen LM
J Neurosci; 2016 Sep; 36(38):9949-61. PubMed ID: 27656032
[TBL] [Abstract][Full Text] [Related]
5. Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum.
Pedrazzi JFC; Sales AJ; Guimarães FS; Joca SRL; Crippa JAS; Del Bel E
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Dec; 111():110352. PubMed ID: 34015384
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine.
Pedrazzi JF; Issy AC; Gomes FV; Guimarães FS; Del-Bel EA
Psychopharmacology (Berl); 2015 Aug; 232(16):3057-65. PubMed ID: 25943166
[TBL] [Abstract][Full Text] [Related]
7. Delta-9-tetrahydrocannabinol potentiates fear memory salience through functional modulation of mesolimbic dopaminergic activity states.
Fitoussi A; Zunder J; Tan H; Laviolette SR
Eur J Neurosci; 2018 Jun; 47(11):1385-1400. PubMed ID: 29776015
[TBL] [Abstract][Full Text] [Related]
8. Neuronal and molecular effects of cannabidiol on the mesolimbic dopamine system: Implications for novel schizophrenia treatments.
Renard J; Norris C; Rushlow W; Laviolette SR
Neurosci Biobehav Rev; 2017 Apr; 75():157-165. PubMed ID: 28185872
[TBL] [Abstract][Full Text] [Related]
9. G protein-coupled receptor signaling in VTA dopaminergic neurons bidirectionally regulates the acute locomotor response to amphetamine but does not affect behavioral sensitization.
Runegaard AH; Dencker D; Wörtwein G; Gether U
Neuropharmacology; 2019 Dec; 161():107663. PubMed ID: 31173760
[TBL] [Abstract][Full Text] [Related]
10. Short-term development of behavioral sensitization to amphetamine requires N-methyl-D-aspartate- and nicotinic-dependent mechanisms in the nucleus accumbens.
Degoulet M; Rostain JC; Abraini JH; David HN
Addict Biol; 2013 May; 18(3):417-24. PubMed ID: 21309959
[TBL] [Abstract][Full Text] [Related]
11. The orexin-1 receptor antagonist SB-334867 reduces amphetamine-evoked dopamine outflow in the shell of the nucleus accumbens and decreases the expression of amphetamine sensitization.
Quarta D; Valerio E; Hutcheson DM; Hedou G; Heidbreder C
Neurochem Int; 2010 Jan; 56(1):11-5. PubMed ID: 19737591
[TBL] [Abstract][Full Text] [Related]
12. Interactions between cannabidiol and Δ
Todd SM; Zhou C; Clarke DJ; Chohan TW; Bahceci D; Arnold JC
Eur Neuropsychopharmacol; 2017 Feb; 27(2):132-145. PubMed ID: 28043732
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic-like effect of retigabine [N-(2-Amino-4-(fluorobenzylamino)-phenyl)carbamic acid ester], a KCNQ potassium channel opener, via modulation of mesolimbic dopaminergic neurotransmission.
Sotty F; Damgaard T; Montezinho LP; Mørk A; Olsen CK; Bundgaard C; Husum H
J Pharmacol Exp Ther; 2009 Mar; 328(3):951-62. PubMed ID: 19098162
[TBL] [Abstract][Full Text] [Related]
14. Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology.
Hudson R; Rushlow W; Laviolette SR
Psychopharmacology (Berl); 2018 Feb; 235(2):447-458. PubMed ID: 29063964
[TBL] [Abstract][Full Text] [Related]
15. Acupuncture attenuates cocaine-induced expression of behavioral sensitization in rats: possible involvement of the dopaminergic system in the ventral tegmental area.
Lee B; Han SM; Shim I
Neurosci Lett; 2009 Jan; 449(2):128-32. PubMed ID: 18992788
[TBL] [Abstract][Full Text] [Related]
16. Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice.
Gomes FV; Issy AC; Ferreira FR; Viveros MP; Del Bel EA; Guimarães FS
Int J Neuropsychopharmacol; 2014 Oct; 18(5):. PubMed ID: 25618402
[TBL] [Abstract][Full Text] [Related]
17. Cholecystokinin modulation of locomotor behavior in rats is sensitized by chronic amphetamine and chronic restraint stress exposure.
Wunderlich GR; Rotzinger S; Bush DE; DeSousa NJ; Vaccarino FJ
Brain Res; 2004 Mar; 1001(1-2):95-107. PubMed ID: 14972658
[TBL] [Abstract][Full Text] [Related]
18. Neuroethological assessment of amphetamine-induced behavioral changes and their reversal by neuroleptics: focus on the amygdala and nucleus accumbens.
Wang Z; Rebec GV
Prog Neuropsychopharmacol Biol Psychiatry; 1998 Jul; 22(5):883-905. PubMed ID: 9723126
[TBL] [Abstract][Full Text] [Related]
19. Pseudoginsenoside-F11 inhibits methamphetamine-induced behaviors by regulating dopaminergic and GABAergic neurons in the nucleus accumbens.
Fu K; Lin H; Miyamoto Y; Wu C; Yang J; Uno K; Nitta A
Psychopharmacology (Berl); 2016 Mar; 233(5):831-40. PubMed ID: 26621348
[TBL] [Abstract][Full Text] [Related]
20. Amphetamine activation of hippocampal drive of mesolimbic dopamine neurons: a mechanism of behavioral sensitization.
Lodge DJ; Grace AA
J Neurosci; 2008 Jul; 28(31):7876-82. PubMed ID: 18667619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
